Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 54NETWORK 13NIH 11INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Lymphoid 7

Conditions

Breast Neoplasms 45Sarcoma 33Lymphoma, Large B-Cell, Diffuse 32Neoplasms 25Lymphoma 20Lymphoma, Non-Hodgkin 19Ovarian Neoplasms 17Lymphoma, Follicular 16Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Lymphoma, B-Cell 11Endometrial Neoplasms 11Recurrence 10Carcinoma, Hepatocellular 8Hodgkin Disease 7Lymphoma, T-Cell, Peripheral 6Hematologic Diseases 6Sarcoma, Kaposi 5Lymphoma, Mantle-Cell 5Leiomyosarcoma 5HIV Infections 5Acquired Immunodeficiency Syndrome 5Multiple Myeloma 4Liposarcoma 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Fallopian Tube Neoplasms 3

Interventions

Brentuximab Vedotin 27pembrolizumab 13Nivolumab 11Dacarbazine 8Vinblastine 7Doxorubicin 7Gemcitabine 6Bendamustine Hydrochloride 6plerixafor 5fludarabine 4Rituximab 4Granulocyte Colony-Stimulating Factor 4Cyclophosphamide 4Azacitidine 4abexinostat 3Melphalan 3Filgrastim 3Etoposide 3Busulfan 3Bleomycin 3umbralisib 2relatlimab 2pegfilgrastim 2mocetinostat 2itacitinib 2givinostat hydrochloride 2givinostat 2fludarabine phosphate 2durvalumab 2cc-486 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Hodgkin Disease × Doxorubicin × Clear all
NCT01712490 2026-02-27

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Takeda

Phase 3 Completed
1,334 enrolled 23 charts
Lymphoid

Hodgkin Disease, Lymphoma

NCT06831370 2026-02-23

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Takeda

Phase 4 Recruiting
124 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

NCT03407144 2026-02-19

MK-3475-667

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
340 enrolled
Lymphoid

Hodgkin Disease

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Takeda

Phase 1/2 Active not recruiting
59 enrolled 63 charts
Lymphoid

Hodgkin Disease

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Seagen Inc.

Phase 2 Terminated
255 enrolled 29 charts
Lymphoid

Hodgkin Disease

NCT02181738 2023-11-28

CheckMate 205

Bristol-Myers Squibb

Phase 2 Completed
294 enrolled 32 charts
Lymphoid

Hodgkin Disease

NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Seagen Inc.

Phase 1 Completed
51 enrolled
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡